Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights? First, we discuss the FDA's decision to halt the use of two Covid-19 antibodies that don't work against Omicron — and the surprising backlash that ensued. Then, acting FDA commissioner Janet Woodcock joins us to dig into the agency's move and discuss the steps for regulation of Covid drugs. We also go over the latest news in the life sciences, including some bad news for Gilead Sciences and a rare victory for a small biotech company.